Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
25.86
Dollar change
-0.30
Percentage change
-1.15
%
IndexRUT P/E20.95 EPS (ttm)1.23 Insider Own1.66% Shs Outstand164.38M Perf Week6.46%
Market Cap4.32B Forward P/E11.91 EPS next Y2.17 Insider Trans-0.10% Shs Float164.12M Perf Month12.26%
Income214.72M PEG0.84 EPS next Q0.44 Inst Own98.36% Short Float / Ratio4.85% / 3.78 Perf Quarter-5.76%
Sales1.59B P/S2.71 EPS this Y390.55% Inst Trans-1.28% Short Interest7.96M Perf Half Y-10.64%
Book/sh8.13 P/B3.18 EPS next Y40.08% ROA10.17% Target Price31.66 Perf Year10.08%
Cash/sh5.33 P/C4.85 EPS next 5Y24.80% ROE17.91% 52W Range20.46 - 31.34 Perf YTD6.46%
Dividend- P/FCF16.98 EPS past 5Y1.24% ROI12.47% 52W High-17.48% Beta0.56
Dividend %- Quick Ratio2.53 Sales past 5Y4.91% Gross Margin82.16% 52W Low26.39% ATR0.82
Employees2280 Current Ratio2.91 Sales Q/Q50.95% Oper. Margin13.51% RSI (14)59.87 Volatility3.05% 3.25%
OptionableYes Debt/Eq0.28 EPS Q/Q171.34% Profit Margin13.50% Rel Volume1.06 Prev Close26.16
ShortableYes LT Debt/Eq0.27 EarningsOct 25 BMO Payout- Avg Volume2.11M Price25.86
Recom2.00 SMA207.34% SMA506.07% SMA200-2.50% Volume2,224,365 Change-1.15%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Resumed JP Morgan Neutral $33
Oct-24-23Upgrade Evercore ISI In-line → Outperform
Oct-17-23Initiated UBS Neutral $31
Nov-03-22Upgrade Piper Sandler Neutral → Overweight $26 → $30
Oct-14-22Upgrade BofA Securities Underperform → Neutral $27 → $25
Aug-16-22Initiated Piper Sandler Neutral $26
Apr-22-22Resumed Goldman Buy $35
Apr-20-22Initiated Goldman Buy $35
Jan-27-22Upgrade Cantor Fitzgerald Hold → Overweight $32
Dec-01-21Initiated Citigroup Neutral $22
Dec-01-23 06:16PM
Nov-29-23 03:15PM
12:01PM
Nov-24-23 11:31AM
Nov-21-23 04:00PM
11:45AM Loading…
11:45AM
Nov-20-23 01:45PM
Nov-16-23 10:30AM
Nov-15-23 08:57AM
07:15AM
07:00AM
Nov-14-23 01:45PM
10:33AM
05:50AM
Nov-13-23 09:50PM
12:45PM Loading…
12:45PM
Nov-10-23 03:00PM
Nov-09-23 11:12AM
Nov-08-23 11:30AM
Nov-07-23 04:00PM
Nov-04-23 12:16PM
Oct-31-23 05:08PM
01:30PM
Oct-26-23 12:00PM
10:37AM
Oct-25-23 12:38PM
09:30AM
07:23AM
07:00AM
Oct-24-23 09:51AM
04:00PM Loading…
Oct-23-23 04:00PM
02:00PM
08:00AM
Oct-19-23 10:01AM
Oct-18-23 06:15PM
04:00PM
Oct-16-23 12:30PM
Oct-13-23 10:45AM
Oct-11-23 12:00PM
Oct-10-23 05:00PM
07:00AM
Sep-21-23 01:00PM
Sep-19-23 11:05AM
Sep-18-23 01:15PM
Sep-15-23 06:15PM
Sep-13-23 10:50AM
Sep-11-23 07:00AM
Sep-08-23 06:15PM
Sep-07-23 03:15PM
11:31AM
09:30AM
07:00AM
Sep-06-23 09:50AM
Sep-05-23 04:00PM
Sep-01-23 06:30PM
11:31AM
Aug-31-23 02:45PM
11:02AM
07:00AM
Aug-30-23 07:00AM
Aug-28-23 10:35AM
Aug-25-23 11:31AM
Aug-21-23 10:45AM
Aug-10-23 05:21AM
Aug-09-23 08:32AM
Aug-04-23 12:36PM
Jul-27-23 10:24AM
Jul-26-23 11:05AM
09:30AM
08:15AM
07:11AM
07:00AM
Jul-25-23 11:21AM
Jul-24-23 01:45PM
10:44AM
Jul-21-23 12:05PM
09:30AM
Jul-20-23 10:02AM
Jul-19-23 04:00PM
11:30AM
10:01AM
Jul-17-23 11:40AM
11:15AM
Jul-13-23 09:40AM
07:56AM
Jul-11-23 08:44AM
Jul-10-23 09:55AM
Jul-06-23 08:00AM
Jul-04-23 07:56AM
Jun-29-23 10:50AM
10:09AM
09:57AM
09:20AM
Jun-28-23 07:30AM
Jun-27-23 01:45PM
09:40AM
Jun-26-23 07:37AM
07:00AM
Jun-22-23 06:25AM
Jun-21-23 02:15PM
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LAURENCIN CATO TDirectorJun 08Option Exercise22.972,63860,59510,117Jun 08 04:31 PM
LAURENCIN CATO TDirectorJun 08Sale31.852,63884,0207,479Jun 08 04:31 PM
LAURENCIN CATO TDirectorJun 07Option Exercise22.972,80064,31610,279Jun 07 05:12 PM
LAURENCIN CATO TDirectorJun 07Sale31.502,80088,2007,479Jun 07 05:12 PM
Nichols Christian ToddSVP, Chief Commercial OfficerMay 30Option Exercise20.4319,634401,12368,118May 30 08:16 PM
Nichols Christian ToddSVP, Chief Commercial OfficerMay 30Sale28.9327,134784,86240,984May 30 08:16 PM
Wysenski NancyDirectorMay 09Option Exercise31.1341,2501,284,11257,079May 10 04:34 PM
Wysenski NancyDirectorMay 09Sale31.2441,2501,288,78615,829May 10 04:34 PM